Department of Haematogenetics, ICMR-National Institute of Immunohaematology, King Edward Memorial Hospital Campus, Mumbai, India.
Hum Mutat. 2020 Apr;41(4):737-748. doi: 10.1002/humu.23973. Epub 2020 Jan 30.
NADH-cytochrome b5 reductase 3 deficiency is an important genetic cause of recessive congenital methemoglobinemia (RCM) and occurs worldwide in autosomal recessive inheritance. In this Mutation Update, we provide a comprehensive review of all the pathogenic mutations and their molecular pathology in RCM along with the molecular basis of RCM in 21 new patients from the Indian population, including four novel variants: c.103A>C (p.Thr35Pro), c.190C>G (p.Leu64Val), c.310G>T (p.Gly104Cys), and c.352C>T (p.His118Tyr). In this update, over 78 different variants have been described for RCM globally. Molecular modeling of all the variants reported in CYB5R3 justifies association with the varying severity of the disease. The majority of the mutations associated with the severe form with a neurological disorder (RCM Type 2) were associated with the FAD-binding domain of the protein while the rest were located in another domain of the protein (RCM Type 1).
NADH-细胞色素 b5 还原酶 3 缺乏症是隐性先天性高铁血红蛋白血症(RCM)的一个重要遗传原因,呈常染色体隐性遗传,在世界各地均有发生。在本次突变更新中,我们全面回顾了 RCM 的所有致病性突变及其分子病理学,并结合来自印度人群的 21 名新患者的分子基础,对 RCM 进行了研究,包括四个新发现的变异:c.103A>C(p.Thr35Pro)、c.190C>G(p.Leu64Val)、c.310G>T(p.Gly104Cys)和 c.352C>T(p.His118Tyr)。在本次更新中,全球范围内已描述了超过 78 种不同的 RCM 变异。对报告的所有 CYB5R3 变异进行分子建模,证实了它们与疾病严重程度的变化有关。与伴有神经障碍的严重形式(RCM 型 2)相关的大多数突变与该蛋白的 FAD 结合域有关,而其余的突变则位于该蛋白的另一个域(RCM 型 1)。